Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-09-14
DOI
10.1038/s41598-017-12222-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mouse models of colorectal cancer as preclinical models
- (2015) Rebecca E. McIntyre et al. BIOESSAYS
- Colorectal cancer models for novel drug discovery
- (2015) Daniel Golovko et al. Expert Opinion on Drug Discovery
- Mouse models of intestinal cancer
- (2015) Rene Jackstadt et al. JOURNAL OF PATHOLOGY
- Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
- (2015) Claudia Allemani et al. LANCET
- Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK
- (2014) A. W. Tolcher et al. CLINICAL CANCER RESEARCH
- A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells
- (2013) I. Puig et al. CLINICAL CANCER RESEARCH
- RAS signaling pathways, mutations and their role in colorectal cancer
- (2013) Kypros Zenonos World Journal of Gastrointestinal Oncology
- Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
- (2012) G. Migliardi et al. CLINICAL CANCER RESEARCH
- A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
- (2011) Suzanne Leijen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling
- (2010) E. Halilovic et al. CANCER RESEARCH
- Nucleolar Targeting of RelA(p65) Is Regulated by COMMD1-Dependent Ubiquitination
- (2010) H. C. Thoms et al. CANCER RESEARCH
- The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
- (2010) U. Banerji et al. CLINICAL CANCER RESEARCH
- A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
- (2010) Jaafar Bennouna et al. INVESTIGATIONAL NEW DRUGS
- Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras-Mutated Colorectal Cancer
- (2010) J. J. Tentler et al. MOLECULAR CANCER THERAPEUTICS
- Finding the tumor copycat: Therapy fails, patients don't
- (2010) Lee M Ellis et al. NATURE MEDICINE
- Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors
- (2010) V. Vaira et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines
- (2009) Kathryn Balmanno et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
- (2008) Alex A. Adjei et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More